Panagora Asset Management’s Standard BioTools LAB Stock Holding History

Panagora Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,555	Closed	-$41K	–	1540
2022 Q1	$41K	Buy	+11,555	New	+$39.9K	﹤0.01%	1510
2021 Q3	–	Sell	-4,481	Closed	-$28K	–	2068
2021 Q2	$28K	Sell	4,481 -10,999	-71%	-$58.8K	﹤0.01%	2130
2021 Q1	$70K	Hold	15,480	–	–	﹤0.01%	2127
2020 Q4	$93K	Sell	15,480 -67	-0.4%	-$440	﹤0.01%	1860
2020 Q3	$115K	Sell	15,547 -304,654	-95%	-$2.1M	﹤0.01%	1749
2020 Q2	$1.28M	Sell	320,201 -98,244	-23%	-$342K	0.01%	842
2020 Q1	$1.06M	Sell	418,445 -351,419	-46%	-$1.15M	0.01%	831
2019 Q4	$2.68M	Buy	769,864 +96,504	+14%	+$339K	0.01%	676
2019 Q3	$3.12M	Buy	673,360 +41,385	+7%	+$326K	0.01%	596
2019 Q2	$7.79M	Buy	631,975 +176,286	+39%	+$2.25M	0.03%	400
2019 Q1	$6.06M	Buy	455,689 +35,446	+8%	+$374K	0.03%	458
2018 Q4	$3.62M	Buy	420,243 +434	+0.1%	+$3.38K	0.02%	565
2018 Q3	$3.14M	Sell	419,809 -16,141	-4%	-$115K	0.01%	675
2018 Q2	$2.6M	Sell	435,950 -78,961	-15%	-$450K	0.01%	778
2018 Q1	$3.01M	Buy	514,911 +115,727	+29%	+$760K	0.01%	723
2017 Q4	$2.35M	Buy	399,184 +7,810	+2%	+$42.8K	0.01%	811
2017 Q3	$1.97M	Buy	391,374 +45,258	+13%	+$190K	0.01%	867
2017 Q2	$1.4M	Buy	346,116 +155,538	+82%	+$737K	0.01%	989
2017 Q1	$1.08M	Buy	190,578 +169,610	+809%	+$1.07M	﹤0.01%	1108
2016 Q4	$153K	Hold	20,968	–	–	﹤0.01%	1831
2016 Q3	$168K	Buy	20,968 +19,295	+1,153%	+$177K	﹤0.01%	1822
2016 Q2	$15K	Hold	1,673	–	–	﹤0.01%	2199
2016 Q1	$14K	Sell	1,673 -7,337	-81%	-$52.9K	﹤0.01%	2176
2015 Q4	$97K	Buy	9,010 +7,337	+439%	+$72K	﹤0.01%	1809
2015 Q3	$14K	Sell	1,673 -3,740	-69%	-$58.9K	﹤0.01%	2187
2015 Q2	$131K	Sell	5,413 -68,963	-93%	-$2.18M	﹤0.01%	1867
2015 Q1	$3.13M	Sell	74,376 -5,440	-7%	-$215K	0.02%	642
2014 Q4	$2.69M	Buy	79,816 +30,657	+62%	+$868K	0.01%	643
2014 Q3	$1.2M	Sell	49,159 -1,713	-3%	-$48.2K	0.01%	959
2014 Q2	$1.5M	Sell	50,872 -2,564	-5%	-$82.2K	0.01%	920
2014 Q1	$2.35M	Buy	53,436 +1,485	+3%	+$65.3K	0.01%	816
2013 Q4	$1.99M	Buy	51,951 +32,964	+174%	+$971K	0.01%	873
2013 Q3	$416K	Buy	18,987 +5,620	+42%	+$110K	﹤0.01%	1421
2013 Q2	$233K	Buy	+13,367	New	+$235K	﹤0.01%	1555

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Panagora Asset Management's LAB Position: Q2 2022 in Review

Panagora Asset Management sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 11,555 shares — an estimated $41K sold.

Panagora Asset Management first reported a position in LAB in Q2 2013 and held it in 34 quarters. The position peaked at $7.79M in Q2 2019. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

Panagora Asset Management reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
Panagora Asset Management sold 11,555 Standard BioTools shares in Q2 2022, an estimated $41K.
Panagora Asset Management first reported a position in Standard BioTools in Q2 2013 and held it in 34 quarters.
Panagora Asset Management's Standard BioTools position peaked at $7.79M in Q2 2019.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on Panagora Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.